SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Basi Ramitpal K | EVP, Human Resources | 2026-08-25 | Tax withholding | 504 | $65K |
| CAGNONI PABLO J | President, Global Head of R&D | 2026-08-19 | Open-market sell 10b5-1 | 10801 | $1.4M |
| CAGNONI PABLO J | President, Global Head of R&D | 2026-08-12 | Open-market sell 10b5-1 | 10803 | $1.3M |
| CAGNONI PABLO J | President, Global Head of R&D | 2026-08-05 | Open-market sell 10b5-1 | 10640 | $1.3M |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-08-05 | Option exercise 10b5-1 | 2207 | $235K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-08-05 | Open-market sell 10b5-1 | 2207 | $274K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-08-03 | Option exercise 10b5-1 | 6055 | $638K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-08-03 | Open-market sell 10b5-1 | 6055 | $729K |
| CAGNONI PABLO J | President, Global Head of R&D | 2026-07-31 | Open-market sell 10b5-1 | 15888 | $1.9M |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2918 | $179K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2284 | $147K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2709 | $167K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 3148 | $216K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2072 | $149K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 9459 | $684K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2623 | $196K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2864 | $222K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 1643 | $132K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 3023 | $252K |
| Mayes Patrick A | EVP & Chief Scientific Officer | 2026-07-31 | Option exercise 10b5-1 | 2623 | $219K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Incyte's risk profile deteriorated across multiple fronts, with the most acute pressure on JAKAFI's revenue cliff: six generic challengers now threaten the product that generates the substantial majority of total revenues, with exclusivity expiring in 2028. Regulatory headwinds compounded the picture — MFN pricing legislation, Medicare/Medicaid reimbursement proposals, and new foreign-income tax exposure all emerged as explicitly flagged material concerns. The failed Escient integration and expanded OPZELURA patent litigation round out a broad, if not yet existential, worsening.
4 company-specific · 5 common-mode
Significant escalation in generic competition threats. JAKAFI now faces six generic manufacturers (vs. one Apotex ANDA previously); OPZELURA faces four (vs. one Padagis). Multiple new patent challenges and litigation increase exclusivity risk materially.
Competition for our products could harm our business and result in a decrease in our revenue. Our products compete, and our product candidates may in the future compete, with currently existing…
New disclosure: JAKAFI revenues comprise substantial majority of total revenues and will decline when patent exclusivity expires in 2028. Material revenue concentration and cliff risk.
RISKS RELATING TO OUR FINANCIAL RESULTS We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may make it difficult for us to…
Added concrete example of failed acquisition: Escient Pharmaceuticals acquired in 2024, then development of two lead compounds stopped. Demonstrates realized integration and commercialization risk.
We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and…
Patent challenges expanded from JAKAFI alone to include OPZELURA, indicating escalated IP litigation risk affecting additional approved products.
We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic…
New disclosure of executive order and MFN pricing legislation threatening material adverse impact on pricing, reimbursement, and profitability. Substantive regulatory risk.
Changes in government pricing policies, including the enactment of “most favored nation” pricing legislation, could adversely affect our business. Our revenue, results of operations, and cash…
New tax risks introduced: One Big Beautiful Bill Act allows R&D expensing (favorable) but increases foreign-derived income tax rates (adverse). SbS Safe Harbor election uncertainty adds compliance complexity and potential adverse tax consequences if not obtained.
Changes in tax laws or regulations could adversely affect our results of operations, business and financial condition. New tax laws or regulations could be enacted at any time, and existing tax laws…
New cross-reference to Medicare/Medicaid drug price reimbursement proposals escalates regulatory risk. Specific legislative threat now explicitly flagged as material concern.
If we are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other…
Added explicit tariff cost risk and increased complexity/cost language. Reflects heightened geopolitical and trade tensions affecting operations.
Risks associated with our operations outside of the United States could adversely affect our business. We have European operations and plan to continue to expand our operations and conduct certain…
Added explicit disclosure of trade policy risks, tariffs, and trade disputes as new business uncertainties affecting operations and supply chain.
Business disruptions and uncertainties could seriously harm our operations, future revenues and financial condition and increase our costs and expenses. Our operations, and those of our CROs…
Incyte has entered into a pricing agreement with CMS affecting access to Jakafi and Jakafi XR through state Medicaid programs and providing relief from future CMS pricing mandates (GUARD and GLOBE models). While the company states no material impact on 2026 guidance or future outlook, the agreement represents a material operational and strategic development affecting drug pricing, market access, and regulatory exposure for a major product line. This is a significant business arrangement that does not fit neatly into other categories but is clearly operational in nature.
View raw filing on EDGAR →This is a standard earnings release disclosing Incyte's Q2 2026 financial results, including total revenue of $1.67 billion (up 38% YoY), total net sales of $1.49 billion (up 40% YoY), and updated full-year 2026 guidance. The press release covers operating results, product-level sales performance, and business updates, which is the core content of an Item 2.02 earnings disclosure.
View raw filing on EDGAR →Incyte announced completion of its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestone payments. The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This is a material M&A transaction involving a substantial cash outlay and a late-stage clinical asset that strengthens the company's pipeline.
View raw filing on EDGAR →Incyte announced settlement of litigation with CMS regarding Medicaid rebate rules applied to Opzelura (ruxolitinib) cream. The settlement involves withdrawal of the company's lawsuit and a one-time non-cash benefit of approximately $246 million from reversal of previously established accrual balances, with material improvement to Opzelura's gross-to-net margins going forward. This is a material litigation settlement with significant financial consequences.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Incyte Corporation's Annual Meeting of Shareholders held on June 8, 2026, including voting outcomes on three matters: election of eight directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder vote results disclosure that is material to investors assessing board composition and governance.
View raw filing on EDGAR →Incyte Corporation announced entry into a definitive agreement to acquire Vega Therapeutics, a material acquisition transaction. Although disclosed under Item 8.01 (Other Events), the substance is a binding M&A commitment that would materially affect the registrant's business and financial position, warranting classification as ma_activity rather than a routine administrative disclosure.
View raw filing on EDGAR →